Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
7.05
-0.38 (-5.11%)
At close: Jun 5, 2026, 4:00 PM EDT
7.12
+0.07 (0.99%)
After-hours: Jun 5, 2026, 6:45 PM EDT
Upstream Bio Employees
Upstream Bio had 75 employees as of December 31, 2025. The number of employees increased by 23 or 44.23% compared to the previous year.
Employees
75
Change (1Y)
23
Growth (1Y)
44.23%
Revenue / Employee
$44,293
Profits / Employee
-$2,090,187
Market Cap
383.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | 23 | 44.23% |
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Vanda Pharmaceuticals | 533 |
| Adlai Nortye | 109 |
| Prelude Therapeutics | 79 |
| Century Therapeutics | 78 |
| Compass Therapeutics | 39 |
| vTv Therapeutics | 26 |
| Monopar Therapeutics | 22 |
UPB News
- 3 days ago - Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 3 days ago - Upstream Bio initiated with a Buy at H.C. Wainwright - TheFly
- 19 days ago - Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug - TheFly
- 19 days ago - Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - GlobeNewsWire
- 23 days ago - Upstream Bio price target lowered to $50 from $51 at Mizuho - TheFly
- 24 days ago - Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 24 days ago - Upstream Bio Earnings release: Q1 2026 - Filings
- 24 days ago - Upstream Bio Quarterly report: Q1 2026 - Filings